At CSL, our commitment goes beyond lifesaving therapies. We build support systems and partner with patient advocacy groups to create a strong community. #PatientStories Learn more: https://bit.ly/4d37dbb
Now Accepting Applications for the 2025 Prof Heimburger Awards
CSL offers emerging coagulation specialists five global start-up grants of $25,000 each.
Pictured: CSL Seqirus employee in Holly Springs, U.S.
We have released our 2024 Annual Report Click here to read the Annual Report → | We have announced our 2024 Full Year Financial Results for the period ending June 30th 2024. Click here to view Information and Webcast Recording →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: CSL employees in Melbourne, Australia
12 Sep
10 Sep
At CSL, our culture celebrates diversity, ensuring everyone feels a sense of belonging. With equal opportunities for growth and a commitment to your success, join us in shaping a future where everyone thrives: https://bit.ly/3Zdw7BD #PromisingFutures #CSL
5 Sep
We are thrilled to announce the opening of our new state-of-the-art Multicube manufacturing facility in St. Gallen, Switzerland! With a modular design that can grow cube by cube and sustainability features like heat recovery and on-site solar power, we're set to meet the rising global demand for iron-based therapies. Discover how we're innovating for a healthier, more sustainable future. Watch the video and read more! https://bit.ly/47gJaUS #CSLVifor #Innovation #Sustainability #Healthcare #IronTherapies
5 Sep
MTPConnect has launched a $28.5M Accelerator backing home-grown start-up Innovations for Heart Disease and Diabetes and CSL is a proud partner. Professor Bronwyn Kingwell, Research Portfolio Strategy and Therapeutic Area Lead at CSL says our support of this research commercialisation Accelerator dovetails nicely with our long-term commitment to supporting Australia’s biotech ecosystem. “With the Accelerator’s support, we hope to see increased therapeutic development in cardiovascular disease and diabetes to benefit patients in Australia and around the world,” she said. #CSL
4 Sep
September is National Sickle Cell Awareness Month in the U.S., a time to raise awareness of this blood disease. Millions of people carry the sickle cell trait without showing symptoms, so awareness and testing are crucial. #NationalSickleCellAwarenessMonth
3 Sep
As a rare condition, understanding the root cause of Hereditary Angioedema (#HAE ) is crucial for improving patient management and care. On the latest #HAESpeaks podcast from Hereditary Angioedema Association - HAEA , doctors Raffi Tachdjian and Jay Kashkin dive deep into the critical role of factor XIIa on the HAE pathway. To further your understanding of the condition, listen here: https://bit.ly/3Z8JYJe
3 Sep
At CSL, we believe that when our employees thrive, our entire CSL family flourishes. Explore a wealth of career and development tools, a global employee share plan, study assistance, and more. Plus, enjoy access to our in-office gyms, where our team can stay active and energized, like in this boxing session! #PromisingFutures #CSL Learn more about how we support your well-being: https://bit.ly/3XsgRzm
30 Aug
When you join our team at CSL, you become part of a culture where empowerment fuels innovation. At CSL, we believe in empowering our employees to take initiative, driving excellence in everything we do. #PromisingFutures #CSL Explore our careers: https://bit.ly/3TxWte7
29 Aug
What do you get when you bring together three experts in public health, vaccines, and manufacturing and add a new vaccine manufacturing site? Some terrific conversations about influenza, pandemic preparedness, and CSL’s technical capabilities in Australia. We welcomed the Australian Government Department of Health and Aged Care 's Chief Medical Officer and Head of the interim Australian CDC, Professor Paul Kelly to the CSL Seqirus Tullamarine facility that will provide onshore production capacity for antivenoms for Australia and cell-based influenza vaccines for Australia and the world. #CSL #CSLSeqirus #Tullamarine #Australia #publichealth #vaccines #influenza #DrivenByOurPromise
29 Aug
Vaccination for #influenza reduces the risk of severe disease. The Centers for Disease Control and Prevention (CDC) is focused on educating people about the importance of staying up to date on the latest vaccinations. During National Immunization Awareness Month, CSL joins the #CDC in encouraging people to speak with their healthcare providers about the vaccinations that are right for people of all ages. Learn more about CSL: https://bit.ly/3Z4cdsB #CSLSeqirus #CSL #DrivenByOurPromise #NIAM
